Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Notoriety Bias or True Ocular Toxicity?

Studied

Researchers examined whether reports linking semaglutide to a type of optic-nerve injury reflected reporting patterns or drug effects.

Who / model

They analysed US adverse-event reports from 2018 through the second quarter of 2026 and genetic proxies for GLP-1 receptor activity. Report and genetic sample sizes are not stated.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Reporting increased after a July 2024 publication, while comparator reporting stayed stable. The genetic-proxy analysis found no statistically clear effect on the examined eye measures. The authors interpreted these patterns as reporting bias; adverse-report frequency is not a measured incidence rate among treated patients.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary